Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries

BackgroundThe Xpert MTB/RIF assay has garnered significant interest as a sensitive and rapid diagnostic tool to improve detection of sensitive and drug resistant tuberculosis. However, most existing literature has described the performance of MTB/RIF testing only in study conditions; little information is available on its use in routine case finding. TB REACH is a multi-country initiative focusing on innovative ways to improve case notification.MethodsWe selected a convenience sample of nine TB REACH projects for inclusion to cover a range of implementers, regions and approaches. Standard quarterly reports and machine data from the first 12 months of MTB/RIF implementation in each project were utilized to analyze patient yields, rifampicin resistance, and failed tests. Data was collected from September 2011 to March 2013. A questionnaire was implemented and semi-structured interviews with project staff were conducted to gather information on user experiences and challenges.ResultsAll projects used MTB/RIF testing for people with suspected TB, as opposed to testing for drug resistance among already diagnosed patients. The projects placed 65 machines (196 modules) in a variety of facilities and employed numerous case-finding strategies and testing algorithms. The projects consumed 47,973 MTB/RIF tests. Of valid tests, 7,195 (16.8%) were positive for MTB. A total of 982 rifampicin resistant results were found (13.6% of positive tests). Of all tests conducted, 10.6% failed. The need for continuous power supply was noted by all projects and most used locally procured solutions. There was considerable heterogeneity in how results were reported and recorded, reflecting the lack of standardized guidance in some countries.ConclusionsThe findings of this study begin to fill the gaps among guidelines, research findings, and real-world implementation of MTB/RIF testing. Testing with Xpert MTB/RIF detected a large number of people with TB that routine services failed to detect. The study demonstrates the versatility and impact of the technology, but also outlines various surmountable barriers to implementation. The study is not representative of all early implementer experiences with MTB/RIF testing but rather provides an overview of the shared issues as well as the many different approaches to programmatic MTB/RIF implementation.

[1]  Brad Wieners,et al.  Reality check , 2018, Nature Energy.

[2]  A. Harries,et al.  In reply to 'Should Xpert® MTB/RIF be rolled out in low-income countries?' [Correspondence]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[4]  A. Van Deun,et al.  Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  A. Ramsay,et al.  Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? , 2013, European Respiratory Journal.

[6]  A. Codlin,et al.  Novel methodology to assess sputum smear microscopy quality in private laboratories , 2012, BMC Infectious Diseases.

[7]  Grant Theron,et al.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial , 2014, The Lancet.

[8]  J. O’Grady,et al.  Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. , 2013, The Lancet. Infectious diseases.

[9]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[10]  Alimuddin Zumla,et al.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. , 2013, The Lancet. Infectious diseases.

[11]  M. Pai,et al.  Promise versus Reality: Optimism Bias in Package Inserts for Tuberculosis Diagnostics , 2012, Journal of Clinical Microbiology.

[12]  Madhukar Pai,et al.  Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis , 2011, PLoS medicine.

[13]  A. Diacon,et al.  Xpert MTB/RIF Assay for Diagnosis of Pleural Tuberculosis , 2011, Journal of Clinical Microbiology.

[14]  Morten Ruhwald,et al.  Point‐of‐care diagnosis of tuberculosis: Past, present and future , 2013, Respirology.

[15]  Anna Vassall,et al.  Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis , 2011, PLoS medicine.

[16]  S. Lawn,et al.  High Diagnostic Yield of Tuberculosis From Screening Urine Samples From HIV-Infected Patients With Advanced Immunodeficiency Using The Xpert MTB/RIF Assay , 2012, Journal of acquired immune deficiency syndromes.

[17]  Madhukar Pai,et al.  Tuberculosis diagnosis--time for a game change. , 2010, The New England journal of medicine.

[18]  P. V. van Helden,et al.  The Diagnostic Performance of the GenoType MTBDRplus Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay , 2012, Journal of Clinical Microbiology.

[19]  D. Williamson,et al.  An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. , 2012, Diagnostic microbiology and infectious disease.

[20]  H. Zar,et al.  Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  N. Dendukuri,et al.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.

[22]  J. V. Gorkom Rapid Implementation of the Xpert MTB/RIF diagnostic test , 2012 .

[23]  N. Engel,et al.  Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries , 2012, PLoS medicine.

[24]  R. Gie,et al.  Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF Assay: a pilot study. , 2012, The Pediatric infectious disease journal.

[25]  Carlton A. Evans,et al.  GeneXpert—A Game-Changer for Tuberculosis Control? , 2011, PLoS medicine.